The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 22, 2015
Filed:
Sep. 03, 2014
Korea Research Institute of Bioscience and Biotechnology, Daejeon, KR;
Misun Won, Daejeon, KR;
Kyung-Sook Chung, Daejeon, KR;
Young Joo Kim, Daejeon, KR;
Hye Kyung Hong, Busan, KR;
Young Il Yeom, Daejeon, KR;
Chae Ok Yun, Seoul, KR;
Yu-Kyoung Oh, Seoul, KR;
Kyung Bin Song, Daejeon, KR;
Hee Gu Lee, Daejeon, KR;
Eun Young Song, Seoul, KR;
Young Ho Kim, Seoul, KR;
Moon Hee Kim, Seoul, KR;
Kyeong-Eun Jung, Anyang-si, KR;
Korea Research Institute of Bioscience and Biotechnology, Daejeon, KR;
Abstract
The present invention provides a pharmaceutical composition for treating cancer, comprising at least one selected from deoxyribonucleic acids (DNA) for encoding small interfering RNA (siRNA) which complementarily binds to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, represented by sequence number 3, sequence number 5, and sequence number 7 to inhibit the intracellular expression of the FLJ25416 gene, antisense RNA which inhibits expression of the FLJ25416 gene, and short hairpin RNA (shRNA) which inhibits expression of the FLJ25416 gene. As the siRNA, which is complementary to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, the antisense RNA, and the shRNA, according to the present invention, inhibit expression of the FLJ25416 gene which is known to be expressed in cancer cells, and thus kill cancer cells, the composition of the present invention can be used as a novel anti-cancer agent.